Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Coswig – page 9

1 038 clinical trials in Coswig, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Coswig at a glance
1 038
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 038 trials in Coswig

Open in trial search

Study of Rinatabart Sesutecan with glatiramer acetate in patients with advanced gastrointestinal cancers

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Genmab A/S

Study of Camoteskimab and Sodium Chloride Placebo in Adults with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camoteskimab
  • Sponsor:Apollo Therapeutics Limited

First‑line Study of RMC‑9805 with Investigator’s Choice Chemotherapy Drug Combination vs Chemotherapy Alone in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Adenocarcinoma

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Zoldonrasib
  • Sponsor:Revolution Medicines Inc.

A Phase 3 Study of Sapablursen Compared with Placebo in Adults with Polycythemia Vera

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sapablursen
  • Sponsor:Deciphera Pharmaceuticals Inc.

Azenosertib versus drug combination in platinum‑resistant high‑grade serous ovarian, fallopian tube or primary peritoneal cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azenosertib
  • Sponsor:K-Group Beta Inc.

Phase 2 study of MK-7262 and enlicitide decanoate in adults with high lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enlicitide decanoate
  • Sponsor:Merck Sharp & Dohme LLC

Phase III Randomized Open‑Label Trial of BNT324 vs Docetaxel Plus Prednisone in Patients with Metastatic Castration‑Resistant Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BNT324
  • Sponsor:BioNTech SE

Phase 3 Study of Romiplostim Combined with Prednisolone versus Prednisolone Alone in Adults with Previously Untreated Primary Immune Thrombocytopenia (ITP)

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:Amgen Inc.

Randomized trial of irinotecan drug combination versus standard therapy as first-line treatment in patients with locally advanced or metastatic small bowel adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Study of YMI024 to Reduce Inflammation in Adults with Stable Coronary Artery Disease and Elevated hsCRP

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Novartis Pharma AG

Phase IIb Study of AZD8965 versus Placebo in Adults with Idiopathic Pulmonary Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AZD8965
  • Sponsor:AstraZeneca AB

Efficacy and Safety of JNJ-78934804 (guselkumab and golimumab) in Adults with Moderately to Severely Active Ulcerative Colitis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Coswig

What the registry says about research in the country

01 Pulmonary Fibrosis Research

Ongoing clinical trials focusing on Progressive Pulmonary Fibrosis (PPF) and Idiopathic Pulmonary Fibrosis (IPF), evaluating innovative inhaled treatments to improve lung function and patient outcomes.

  • Inhaled Treprostinil Studies
  • Long-term Safety Evaluations
  • FVC Measurements

Multiple Phase 3 studies are examining both short and long-term treatment effects in patients with fibrotic conditions.

02 Interstitial Lung Disease Studies

Research initiatives targeting Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs), with trials designed to assess new therapeutic approaches for reducing lung function decline.

  • Novel Drug Evaluations
  • Disease Progression Monitoring
  • Treatment Safety Assessments

Comprehensive studies examining both established and experimental treatments for various forms of lung fibrosis.

03 Advanced Therapeutic Development

Investigation of new compounds including bexotegrast and other innovative medications for treating various forms of pulmonary fibrosis and related conditions.

  • Placebo-controlled Studies
  • Efficacy Measurements
  • Long-term Treatment Effects

Multiple parallel studies are evaluating different therapeutic approaches to address various manifestations of fibrotic lung disease.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.